Web17. mar 2024. · MannKind’s Technosphere® technology is an innovative, dry-powder formulation technology that allows medication to be delivered to the lungs. MannKind has successfully prepared Technosphere formulations of anionic and cationic drugs, hydrophobic and hydrophilic drugs, proteins, peptides and small molecules. ... Web19. apr 2024. · Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA. WESTLAKE VILLAGE, Calif. and DANBURY, Conn., April 19, 2024 (GLOBE NEWSWIRE ...
Dry powder inhalers: upcoming platform technologies for …
Web08. avg 2024. · This is very important as it can be seen as a key driver for the future of MannKind. If the Technosphere technology is proven to be more effective than traditional methods of drug delivery, then ... Web24. maj 2024. · Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s innovative Technosphere® inhalation technology. MannKind and United … mass effect zoom background
About MannKind
Web19. apr 2024. · Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDAWESTLAKE VILLAGE, Calif. and DANBURY, Conn., April 19, 2024 (GLOBE NEWSWIRE ... Web11. jun 2007. · Technosphere ® Insulin Technology. ... Technosphere ® (MannKind Corp., Valencia, CA) inhalation powder is a novel delivery platform that enables large peptides to be delivered via the pulmonary route. Technosphere Insulin (TI), a formulation of regular human insulin, has been specifically designed to facilitate efficient transport via … Web19. apr 2024. · Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA. April 19, 2024 06:00 ET Source: … hydrofarm active air